NP-delivered intervention fails to reduce early symptom burden during chemo
the ONA take:
A nurse practitioner (NP)-delivered symptom management intervention did not appear to reduce symptom burden compared with standard care among patients initiating chemotherapy for nonmetastatic cancer, a new study published in the journal Cancer has shown.
For the study, researchers sought to determine whether an NP-delivered symptom management intervention would reduce patient-reported symptom burden among patients initiating chemotherapy for nonmetastatic cancer.
Researchers enrolled 120 patients with nonmetastatic breast, colorectal, or lung cancer and randomly assigned them to receive standard care alone or standard care plus the intervention.
Patients assigned to the intervention group received telephone calls from their oncology NP during the week after each of the first two visits for chemotherapy administration.
Results showed that 50.8% of patients reported at least one physical symptom at the time of the first chemotherapy administration visit. Researchers found that the number of symptoms, symptom distress, and satisfaction with care increased, while the risk for anxiety symptoms decreased.
The likelihood of depression symptoms did not change over time. There was no difference in the reduction of patient-reported symptom burden between the two arms.
The findings suggest that it is important to continue identifying strategies to improve symptom management, particularly early symptoms, during chemotherapy for patients with nonmetastatic disease.
A nurse practitioner-delivered symptom management intervention did not appear to reduce symptom burden.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|